The goal of this clinical trial is to compare the postprandial glucose and insulin responses after different fruit snacks compared to confection control in a healthy population
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
completed
Actual enrollment (reported)
24 participants
Study completion date
October 31, 2024
Actual (reported)
Listed locations
1 countries · 1 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
blood glucosemetabolic healthcranberry fruit snacks
Outcome Measures
Primary Outcomes (1)
Blood glucose iAUC - 2 hours
The primary outcome variable will be glucose incremental area under the curve (iAUC) from pre-product consumption to 120 min (iAUC0-120 min)
2 hours
Secondary Outcomes (3)
Blood glucose change
2 hours
blood glucose time to max concentration
2 hours
Blood insulin
2 hours
Study Arms (6)
First product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Second product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Interventions
Fruit snack 1Dietary supplement
Fruit snack with original level of sugar
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Third product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Fourth product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Fifth product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Sixth product order: order not stated to protect study blinding
EXPERIMENTAL
Participant will receive each of the 5 study products sequentially in a cross-over design, consuming one study product for one visit, followed by 3-7-day wash-out period before beginning the next product in the sequence
Dietary Supplement: Fruit snack 1Dietary Supplement: Fruit snack 2Dietary Supplement: Fruit snack 3Dietary Supplement: Fruit snack 4Dietary Supplement: Fruit snack 5Dietary Supplement: Confection control
Dietary supplement
Fruit snack with reduced level of sugar
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Fruit snack 3Dietary supplement
Fruit snack with 0 added sugar - formulation 1
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Fruit snack 4Dietary supplement
Fruit snack with 0 added sugar - formulation 2
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Fruit snack 5Dietary supplement
Fruit snack from raisins
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Confection controlDietary supplement
confection
Fifth product order: order not stated to protect study blindingFirst product order: order not stated to protect study blindingFourth product order: order not stated to protect study blindingSecond product order: order not stated to protect study blindingSixth product order: order not stated to protect study blindingThird product order: order not stated to protect study blinding
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Fasting capillary glucose \<110 mg/dL at visit 1.
Willing to avoid consuming high-polyphenol containing foods for 48 h prior to each test visit.
Willing to abstain from alcohol consumption for 24 hours prior to each study visit.
Non-user of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, with no plans to begin use during the study period.
Willing to maintain habitual physical activity level throughout the duration of the study.
Willing to maintain habitual dietary pattern throughout the duration of the study, including stable intake of current vitamins, minerals, supplements and medications not interfering with study outcomes.
Score of 7 to 10 on the Vein Access Scale at visit 1.
No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history.
Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator.
You may not qualify if:
History or presence of clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, or neurological disorders that may affect the participant's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the Investigator.
Uncontrolled hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg) as defined by the blood pressure measured at visit 1
Unstable use (initiation or change in dose) within 30 days of visit 1 of antihypertensive medications.
Unstable use (initiation or change in dose) within 30 days of visit 1 of thyroid hormone replacement medications.
Use of medications or supplements that may influence carbohydrate metabolism within 30 days of visit 1.
Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan, vegetarian) at the discretion of the Clinical Investigator.
Weight loss or gain \>4.5 kg in the 2 months prior to visit 1.
Currently, or planning to be, on a weight loss regimen during the study.
Use of weight loss medication within 90 d of visit 1.
History of gastrointestinal surgery for weight reducing purposes.
History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.
Known allergy or sensitivity to any ingredients or potential allergens contained in the study product.
History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
History of any major trauma or major surgical event within 2 months of visit 1.
Blood donation \>450 mL within 8 weeks of visit 2 or plans to donate blood or plasma during the study period.
+4 more criteria
Contact the study team to confirm eligibility.
Primary Completion
August 30, 2024
Actual (reported)
Study Completion
October 31, 2024
Actual (reported)
Last Updated
July 14, 2025
Record last verified: 2025-07
Data Sharing
IPD Sharing
Will not share
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.